Loading patent…
AssigneesKorea Research Institute of Bioscience and Biotechnology, Seoul National University R&Db Foundation
InventorsMyung Hee KIM, Won-Jae LEE, Su-Man KIM, Shinhye PARK, Kyung-Ah LEE, Eun-Young LEE, Byoung Chan KIM, Chul-Ho LEE, Jungwon HWANG
Estimating the term…
The present invention relates to uses of threonyl-tRNA synthetase (TARS) derived from Akkermansia muciniphila or a fragment thereof as an active ingredient for prevention, alleviation, and treatment of an inflammatory disease. The Akkermansia muciniphila TARS or a fragment thereof according to the present invention promotes the differentiation of M2 macrophages, which are anti-inflammatory macrophages, to multiply macrophages, thereby increasing the secretion of IL-10 as an anti-inflammatory cytokine, leading to the proliferation of B cells to result in an anti-inflammatory effect, and thus was verified to show alleviation effects of not only inflammatory diseases but also immune diseases, infectious diseases, and metabolic diseases accompanied by inflammation, and to have excellent effects in the prevention or treatment of an inflammatory bowel disease (IBD).
A method for preventing or treating an inflammatory disease, the method comprising administering to a subject a composition comprising Akkermansia muciniphila-derived threonyl-tRNA synthetase (TARS) or a fragment thereof as an active ingredient.
A method for differentiation or proliferation of B cells, the method comprising administering to a subject a composition comprising Akkermansia muciniphila-derived TARS or a fragment thereof as an active ingredient.
A method for differentiation or proliferation of M2 macrophages, the method comprising administering to a subject a composition comprising Akkermansia muciniphila-derived TARS or a fragment thereof as an active ingredient.
A composition comprising Akkermansia muciniphila-derived TARS or a fragment thereof as an active ingredient.
Dependencies are inferred from the claim text.